Aims/hypothesis. We carried out global transcript profiling to identify differentially expressed skeletal muscle genes in insulin resistance, a major risk factor for Type II (non-insulin-dependent) diabetes mellitus. This approach also complemented the ongoing genomic linkage analyses to identify genes linked to insulin resistance and diabetes in Pima Indians. Methods. We compared gene expression profiles of skeletal muscle tissues from 18 insulin-sensitive versus 17 insulin-resistant equally obese, non-diabetic Pima Indians using oligonucleotide arrays consisting of about 40,600 transcripts of known genes and expressed sequence tags, and analysed the results with the Wilcoxon rank sum test. We verified the mRNA expression of ten differentially (best-ranked) and ten similarly (worst-ranked) genes using quantitative Real Time PCR.
olism by insulin [1] . Insulin resistance, characterized as decreased insulin action on glucose uptake and metabolism, is a major predictor of Type II diabetes independent of obesity in Pima Indians of Arizona [2] who have a high prevalence of the disease [3] . Under physiological conditions, insulin-stimulated glucose metabolism occurs mainly in skeletal muscle (>80%) and adipose (~5-10%) tissues [4] . Similar to Type II diabetes, insulin resistance clusters in families [5] , and is inherited as a non-Mendelian trait [6] . Since insulin resistance is a pre-diabetic phenotype, it is thought that genes influencing this metabolic abnormality could be fewer than those contributing to the complex diabetic syndrome. Chromosomal regions harbouring susceptibility genes for pre-diabetic phenotypes [7] Type II (non-insulin-dependent) diabetes mellitus is an increasingly common metabolic disease involving abnormal regulation of carbohydrate and lipid metab-and diabetes [8] have been identified using linkage analyses in the Pima population.
The recent advances in genomic research include the utilization of microarrays to monitor the expression of thousands of genes in parallel. Global gene expression or transcriptional profiling has been used to identify molecular markers for various pathological states [9, 10, 11] . In this study we used global gene expression using oligonucleotide microarrays that included transcripts of known genes and Expressed Sequence Tags (ESTs) to identify potentially novel genes in pathways that are dysregulated at the transcript level in the skeletal muscle tissue of insulin-resistant non-diabetic Pima Indians. This approach provides data that can generate new hypotheses on the metabolic impairment that characterizes insulin resistance. Furthermore, this transcriptional profiling approach should complement the genomic linkage and positional cloning of diabetes susceptibility genes in the Pima Indian population by potentially identifying differentially expressed genes located on the chromosomal regions with suggestive linkage to diabetes and insulin resistance.
Subjects and methods
Subjects and clinical procedures. This study was approved by the Tribal Council of the Gila River Indian Community and the Institutional Review Board of the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). All subjects provided written informed consent prior to participation. The subjects in this study were non-diabetic Pima Indians or Tohono O'Odham Indians who were classified as insulin-sensitive (IS, n=18) or insulin-resistant (IR, n=17) based on a twostep hyperinsulinaemic-euglycaemic clamp and were matched for per cent body fat to minimize the differences due to obesity. The anthropometric and metabolic characteristics of the two groups at the time of the muscle biopsy are summarised in Table 1 . All subjects were in good health as assessed by medical history, physical examination and routine blood and urine tests, and none were taking medication at the time of the study.
Volunteers were admitted to the Clinical Research Unit for 8 to 10 days. They were fed a weight maintaining diet (containing 50% of calories as carbohydrates, 30% as fat, and 20% as protein) for 2 to 3 days before metabolic testing. Body composition was measured by dual energy X-ray absorptiometry (DXA) using a total body scanner (DPX-L, Lunar Radiation, Madison, Wis., USA) [12] . Oral glucose tolerance tests using 75 g glucose were carried out after a 12-h overnight fast, and diabetes was defined according to the World Health Organization criteria [13] . Plasma glucose and insulin concentrations were measured in blood samples drawn before glucose ingestion and at 30, 60, 120 and 180 min thereafter. Insulin action was measured at physiologic and supraphysiologic insulin concentrations during a two-step hyperinsulinaemic-euglycaemic glucose clamp [2] . After an overnight fast, a primed continuous intravenous insulin infusion was administered for 100 min at a constant rate of 40 mU·m -2 body surface area·minute -1 (low dose), followed by a second insulin infusion for 100 min at 400 mU·m -2 ·minute -1 (high dose). These infusions achieved steady-state plasma insulin concentrations of 840±250 pmol/l and 13320±3480 pmol/l (Means ± SD), respectively. Plasma glucose concentrations were maintained at about 5.6 mmol/l with a variable infusion of a 20% glucose solution. Rates of insulin-stimulated glucose disposal at physiologic and maximally stimulating insulin concentrations were calculated for the last 40 min of each phase, and corrected for endogenous glucose output (EGO) [14] . During the low dose and baseline, EGO was calculated using a primed (1.11×10 6 Bq), continuous (1.11×10 4 Bq·min -1 ) 3-3 H-glucose infusion [2, 15] ; during the high insulin dose, EGO was assumed to be 0. The glucose disposal rates during the clamp served as the selection criteria for the insulin-sensitive or resistant group. Subjects of a similar percentage of body fat with the highest or lowest glucose disposal rates were classified into the insulin-sensitive (IS) or insulin-resistant (IR) group, respectively. Indirect calorimetry using a ventilated hood system was used to calculate the rates of insulin-stimulated oxidative and non-oxidative glucose disposal [16] . All measurements derived from the glucose clamp were normalized to estimated metabolic body size (EMBS, which equals fat-free mass +17.7 kg) [17] .
Percutaneous skeletal muscle biopsies of the vastus lateralis muscle were carried out in the morning after a 12-h overnight Y., USA). The cRNA was purified using RNeasy Mini kit (Qiagen, Santa Clarita, Calif., USA) and randomly fragmented by heat and alkaline treatment prior to hybridization to Affymetrix GeneChips. For verification using TaqMan Real Time PCR (Q-RT-PCR), single-stranded oligo-dT primed cDNA were synthesized from either the available total RNA (pre-treated with DNA-free reagent from Ambion, Austin, Tex., USA) or mRNA of the majority of subjects using the Advantage RT-for-PCR kit (Clontech, Palo Alto, Calif., USA).
Hybridization, staining, scanning and analysis of image.
The hybridization solution consisted of the 0.05 µg/µl fragmented cRNA sample, 50 pmol/l of a control biotinylated oligonucleotide for image alignment, biotin-labelled bacterial and phage cRNAs for hybridization control (1.5 pmol/l bioB, 5 pmol/l bioC, 25 pmol/l bioD, 100 pmol/l Cre), and 0.1 mg/ml degraded herring sperm DNA in hybridization buffer. The hybridization mixture was heated to 99°C for 5 min and equilibrated at 45°C for 5 min before hybridization in the oligonucleotide array chamber at 45°C for 16 to 17 h. Each hybridization sample was hybridized to the Affymetrix GeneChip Hu6800 Array (Santa Clara, Calif., USA) and Human 35 K set consisting of about 5600 unambiguous full-length cDNAs (after masking for the ambiguous probe set designs using the class AB mask as per the manufacturer's instruction that filtered out probe sets containing less than 10 unambiguous probe pairs in the Hu6800 array) and about 35,000 clustered human EST transcripts, respectively. After hybridization, the solution was removed and the probe arrays were washed and stained using the GeneChip Fluidics station protocol EukGE-WS2, as described previously [18] . The protocol consisted of non-stringent and stringent washes after hybridization, followed by a staining procedure using streptavidin-phycoerythrin solution (SAPE), and a post-stain wash. Signal amplification was achieved using antibody against streptavidin, after a final wash. The probe arrays were then scanned twice using a scanning confocal microscope (GeneChip scanner, Molecular Dynamics and Affymetrix, Santa Clara, Calif., USA). The stored images were aligned and analysed using the GeneChip software MAS 4.0 (Affymetrix) as per manufacturer's instruction. Signal intensity for each cDNA or EST entry (represented as "value" in Table 4 ) was calculated as the difference of filtered Perfect Match (PM) probes minus Mismatch (MM) probes. The signal intensities were normalized to the mean intensity of all the genes represented on the array, and then scaled to the image intensity of a randomly chosen sample pool (IS1) for that particular array. The comprehensive list on signal intensity and present/absent calling for each cDNA/EST in every sample pool can be found on http://www.ncbi.nlm.nih.gov/geo/; accession numbers GSE64-73.
GeneChip data analysis. We only considered cDNA or EST entries that were called "present" by the GeneChip software in at least three sample pools of one group (either IS or IR) versus none in the other group. For example, we would exclude an entry that was present in only two IS sample pools and two IR pools, but we would include an entry that was present in three IS pools versus no IR pool. Excluded entries were designated "below detection threshold." From the 40600 cDNAs/ESTs represented on the arrays, there were only 10831 cDNAs/ESTs that met the inclusion criteria. We then applied the non-parametric statistical analysis, Wilcoxon Rank Sum test to the average difference values of the cDNAs and ESTs in all sample pools, and listed those with a p value of less than or equal to 0.05 (hereafter called the best-ranked list).
Quantitative Q-RT-PCR. Verification of transcript quantity in several selected cDNAs/ESTs was carried out using TaqMan Real Time PCR (Q-RT-PCR) on cDNA from individual samples that had enough remaining total RNA or mRNA. The primer pairs and probe for each cDNA/EST were designed using Primer Express software (Applied Biosystems, Foster City, Calif., USA), and are available upon request. The quantification was carried out using the standard protocol of ABI PRISM 7700 (Applied Biosystems). For each primer and probe set, a standard curve was generated by a serial dilution of a cDNA sample synthesized from muscle RNA of a healthy subject that was done in triplicate. Each sample was run in duplicate and the mean value of the duplicate was used to calculate the mRNA expression. The transcript quantity of a particular cDNA/EST in each cDNA sample was normalized to that of cyclophilin using the TaqMan Pre-Developed Assay Reagent for human endogenous controls (Applied Biosystems).
Q-RT-PCR data analysis.
Differential gene expression between the IR and the IS groups as measured using Q-RT-PCR was analysed using one-tailed Student's t test, since we hypothesized that the relative abundance of each transcript in the IS and the IR groups measured by the Q-RT-PCR method would be the same as that measured by the oligonucleotide array analysis.
Results
Oligonucleotide microarray analysis. There were 195 differentially expressed transcripts in IS versus IR groups as assessed by the rank sum test. These transcripts included nine ESTs that contained repetitive elements and one EST that was no longer documented in the GenBank database (http://www.ncbi.nih.gov/ Genbank/). The remaining 185 transcripts were categorized based on their (putative) functions as well as their known chromosomal locations to complement the positional cloning strategy for diabetes susceptibility gene(s). Subsets of functionally known genes with higher expression in either the IS or the IR group are listed ( Table 2, 3 ). The expression of some candidate genes previously suggested to be transcriptionally dysregulated in diabetic and/or insulin resistant people are shown in Table 4 .
Q-RT-PCR verification.
For verification of differential mRNA expression using a different method (Q-RT-PCR), we selected ten out of the best-ranked 185 differentially expressed transcripts ( Table 5 ). The ten transcripts were called "present" in all ten sample pools, and contained sequence regions that allowed the design of specific primer-probe sets for this assay. Nine of the ten transcripts were derived from known cDNAs and the remaining transcript was an EST representing a gene with an unknown function. As a comparison, we also quantified ten transcripts that were similarly called "present" in all ten sample pools, but were not differentially expressed as assessed by the rank sum test (i.e. worst-ranked) in the same individual cDNA samples ( Table 5 ). The ten worst-ranked transcripts were chosen to be in a similar range of expression in the GeneChip analysis as the ten bestranked ones. We measured the expression of these transcripts in individual samples (13 IS and 10-12 IR) that had enough remaining RNA available. The average values of each transcript in the IS and the IR groups obtained by the GeneChip analysis and the Q-RT-PCR method were compared. Out of the ten best-ranked transcripts that were differentially expressed in the IS and IR groups by GeneChip analysis, two transcripts, Insulin Receptor Substrate 1 (IRS1) and Insulin-like Growth Factor Binding Protein 5 (IGFBP5), were confirmed to be differentially expressed by Q-RT-PCR (Table 5 ). None of the ten worst-ranked transcripts showed a difference between the IS and IR groups by Q-RT-PCR (Table 5 ).
Discussion
We have used global microarray analysis to identify potential candidate genes for insulin resistance in skeletal muscle tissues of Pima Indians. We analysed the data above detection threshold using the Rank Sum Test to select the transcripts that were differentially expressed (the best-ranked transcripts). The resulting number of 195 transcripts was fewer than the expected 541 transcripts (out of 10,831) that should have achieved a p value of less than or equal to 0.05. This could be due, at least partly, to redundancies in the cDNA/EST representation on the probe arrays resulting in less than 10,831 unique transcripts. Knowledge of new genes that are differentially regulated in insulin resistance can generate new hypotheses on molecular mechanisms of the syndrome. Furthermore, differentially expressed genes in chromosomal regions with suggestive linkage to diabetes and insulin action in Pima and other populations would serve as candidate susceptibility genes for insulin resistance and diabetes.
We also checked the expression of some genes previously suggested to be transcriptionally dysregulated in diabetic and insulin-resistant people, which could be either primary causes or secondary effects of the insulin resistance state, e.g. modulated by chronically higher plasma insulin or glucose concentrations. There were no statistically significant differences in the expression of these genes in the microarray data, which could be due to the small number of samples in each group and lower sensitivity of microarray technology compared to RT-PCR [19] . The expression of some genes are below detection threshold, and determination of differential expression for such probe sets is deemed unreliable [20] .
The expensive cost of the GeneChips did not allow experimental replication that would be necessary to assess the signal intensity variance for each probe set and the traditional confidence level. As there were thousands of genes represented on the GeneChips, the statistical analysis involved multiple testing issues. A traditional way to test for statistical significance in the face of such multiple testing is to apply the Bonferroni correction or a related step-up or step-down procedure [21] , which would result in very small alpha levels. For example, an experiment-wise alpha level of 0.05 with 10,000 genes would require a p-value of 5×10 -6 ; this might result in absurdly low power for realistic sample sizes and would disregard many biologically significant changes [22] . Thus, we estimated the number of genes with true expression differences between the IS and IR groups by empirical testing using a different method (Q-RT-PCR).
We carried out Q-RT-PCR on the ten best-ranked and ten worst-ranked transcripts in the majority of subjects individually. This empirical testing confirmed about 20% of the differentially expressed genes and 100% of the similarly expressed genes. Despite the confirmation of true negative results in the data set above detection threshold, the 20% enrichment in true positive result was low and indicated that the differential expression of the other best-ranked genes has to be confirmed with a different method or a larger number of samples. The high false positive rate could be due to either type I error in the microarray analysis or type II error in the RT-PCR analysis. Nevertheless, the 185 potentially differentially expressed genes can be used to generate new hypotheses on molecular features of insulin resistance and to complement the positional cloning effort on diabetes susceptibility genes.
Insulin receptor substrate 1 (IRS1) was one of the best-ranked transcripts confirmed to be differentially expressed between the IR and the IS groups. Considering that IRS1 mRNA was reduced by a higher plasma insulin concentration during a euglycaemic-hyperinsulinaemic clamp in healthy subjects [23] , our result can be explained by normal insulin regulation of IRS1 expression in the IR subjects, i.e. the decreased muscle IRS1 expression is secondary to hyperinsulinaemia induced by insulin resistance. This explanation would support the hypothesis that muscle IRS1 regulation is not affected by insulin resistance in diabetic patients [24] . Alternatively, the reduced IRS1 expression in the IR subjects could play a role in the development of insulin resistance in non-diabetic subjects and could be due to genetically determined abnormal regulation of the IRS1 gene or altered function of transcription factors regulating IRS1 transcription. This explanation, together with the gene location on 2q36 in the vicinity of a suggestive linkage to insulin action in Pima Indians [7] , lead to the possibility of a polymorphism(s) in the IRS1 gene that regulates its expression. The frequency of the Gly972Arg polymorphism in the IRS1 gene is higher in Type II diabetic patients of some, but not all, studied ethnic groups [25, 26, 27, 28] . This polymorphism is absent, or at least very rare, in Pima Indians [29] ; thus, the differentially regulated IRS1 expression in the subjects of our study was not associated with Gly972Arg polymorphism. The IRS1 gene has been screened for single nucleotide polymorphisms (SNPs), and preliminary data indicate that SNPs in the gene are associated with diabetes in Pima Indians [30] . IRS1 was one of the transcripts in insulin signaling pathway with higher expression in the IS group. The other transcripts encode PPP1R11 and PPP1R2, regulatory subunits of protein phosphatase-1 (PP1), a key enzyme that regulates the activity of glycogen synthase. PPP1R2 has been proposed to act as a molecular "chaperone" that aids the folding of newly synthesized PP1 into a biologically active conformation [31, 32] and it has been shown to translocate to the nucleus during the S-phase of cell cycle [33] . There were no polymorphisms in the exons and exon-intron splice junctions of the PPP1R2 gene in selected Pima Indian subjects [34] but potential polymorphisms in the regulatory region of the gene might account for the differential gene expression. PPP1R11 is a heat-stable inhibitor of PP1 encoded by a gene on chromosome 6p21 that was previously known as the Hemochromatosis Candidate Gene V [35] . Of interest, an apparent pseudogene of PPP1R2 is also located on chromosome 6p21 [36, 37] . Both PPP1R11 and PPP1R2 serve as candidate genes for insulin resistance.
Apart from IRS1, the other gene in the ten selected best-ranked list with confirmed lower mRNA expressions in the IR subjects was IGFBP5 (on chromosome 2q33-36), a modulator of insulin growth factor 1 in inducing muscle differentiation [38, 39, 40] . The serum protein concentration of IGFBP5 was lower in diabetic patients compared to the control subjects [41] , and diabetic rat kidney contains reduced IGFBP5 mRNA concentrations [42] . Nevertheless, the expression of IGFBP5 in skeletal muscle is not altered acutely by nutrients and insulin [43] . Note that a transcriptional regulator of myogenesis, LIM domain Only 4 (LMO4), was assessed to be lower in the IR group by the GeneChip analysis. These findings lead to a hypothesis that insulin resistance is associated with dysregulation of myogenic development.
One of the objectives of this study is to complement the positional cloning effort currently ongoing in the Pima population. The genes encoding many of these transcripts had been localized to particular chromosomal regions, and a few are in regions with suggestive linkage to diabetes and insulin action in Pima Indians. One such gene on chromosome 11q23 encodes a rho guanine nucleotide exchange factor (ARHGEF12). Preliminary findings indicate an association between several SNPs in the gene with insulin sensitivity in Pima Indians [44] . This result provides evidence for the utility of transcriptional profiling to identify new candidate genes as a complementary approach to positional cloning.
Another chromosomal region with suggestive linkage to diabetes in the Pima population is 1q21 that harbours many genes, including phosphoprotein enriched in diabetes or phosphoprotein enriched in astrocytes 15 (PED/PEA15). The mRNA concentration of PED/PEA15 is increased in fibroblasts, skeletal muscle and adipose tissue of Type II diabetic subjects [45] . In line with this finding, our GeneChip analysis indicated that the PED/PEA15 was expressed marginally higher in the IR versus IS groups. Despite the recent finding that several SNPs in the non-coding region of the PEA15 gene were not associated with diabetes in 50 affected and 50 control Pimas [46] , this could still be a good candidate gene for insulin resistance.
In summary, we have carried out a global transcriptional profiling of insulin-resistant and insulin-sensitive skeletal muscle tissue. This approach, coupled with the current metabolic knowledge and the positional cloning efforts, provides several novel candidate genes that can generate new hypotheses on the pathophysiology of insulin resistance and the development of Type II diabetes.
